Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Intratherapeutic Biokinetic Measurements, Dosimetry Parameters Estimate, and Monitoring Treatment Efficacy using Cerenkov Luminescence Imaging in Preclinical Radionuclide Therapy.

Vilhelmsson Timmermand, Oskar LU ; Tran, Thuy LU ; Strand, Sven-Erik LU and Axelsson, Johan (2015) In Journal of Nuclear Medicine 56(3). p.444-449
Abstract
In recent years, there has been an increasing amount of interest in non-invasive Cerenkov Luminescence Imaging (CLI) of in vivo radionuclide distribution in small animals, a method proven as a high-throughput modality for confirmation of tracer uptake. 11B6 is an IgG1 monoclonal antibody that is specific for free human kallikrein-related peptidase 2 (hK2) an antigen abundant in malignant prostatic tissue. Free hK2 was targeted in prostate cancer xenografts using (177)Lu-labeled 11B6 in either murine or humanized forms for radionuclide therapy (RNT). In this setting, CLI was investigated as a tool for providing parameters of dosimetric importance during RNT. First, longitudinal imaging of biokinetics using CLI and single-photon emission... (More)
In recent years, there has been an increasing amount of interest in non-invasive Cerenkov Luminescence Imaging (CLI) of in vivo radionuclide distribution in small animals, a method proven as a high-throughput modality for confirmation of tracer uptake. 11B6 is an IgG1 monoclonal antibody that is specific for free human kallikrein-related peptidase 2 (hK2) an antigen abundant in malignant prostatic tissue. Free hK2 was targeted in prostate cancer xenografts using (177)Lu-labeled 11B6 in either murine or humanized forms for radionuclide therapy (RNT). In this setting, CLI was investigated as a tool for providing parameters of dosimetric importance during RNT. First, longitudinal imaging of biokinetics using CLI and single-photon emission computed tomography (SPECT) was compared. Second, the CLI signal was correlated to quantitative ex vivo tumor activity measurements. Finally, CLI was used to monitor the radionuclide treatment and it was found that the integrated CLI radiance correlated well with subject-specific tumor volume reduction. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Nuclear Medicine
volume
56
issue
3
pages
444 - 449
publisher
Society of Nuclear Medicine
external identifiers
  • pmid:25655628
  • wos:000350631700045
  • scopus:84928166944
  • pmid:25655628
ISSN
0161-5505
DOI
10.2967/jnumed.114.148544
language
English
LU publication?
yes
id
a8b427dc-ab3d-4074-a781-fc1208389a89 (old id 5145350)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25655628?dopt=Abstract
date added to LUP
2016-04-01 10:55:51
date last changed
2022-04-12 18:57:48
@article{a8b427dc-ab3d-4074-a781-fc1208389a89,
  abstract     = {{In recent years, there has been an increasing amount of interest in non-invasive Cerenkov Luminescence Imaging (CLI) of in vivo radionuclide distribution in small animals, a method proven as a high-throughput modality for confirmation of tracer uptake. 11B6 is an IgG1 monoclonal antibody that is specific for free human kallikrein-related peptidase 2 (hK2) an antigen abundant in malignant prostatic tissue. Free hK2 was targeted in prostate cancer xenografts using (177)Lu-labeled 11B6 in either murine or humanized forms for radionuclide therapy (RNT). In this setting, CLI was investigated as a tool for providing parameters of dosimetric importance during RNT. First, longitudinal imaging of biokinetics using CLI and single-photon emission computed tomography (SPECT) was compared. Second, the CLI signal was correlated to quantitative ex vivo tumor activity measurements. Finally, CLI was used to monitor the radionuclide treatment and it was found that the integrated CLI radiance correlated well with subject-specific tumor volume reduction.}},
  author       = {{Vilhelmsson Timmermand, Oskar and Tran, Thuy and Strand, Sven-Erik and Axelsson, Johan}},
  issn         = {{0161-5505}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{444--449}},
  publisher    = {{Society of Nuclear Medicine}},
  series       = {{Journal of Nuclear Medicine}},
  title        = {{Intratherapeutic Biokinetic Measurements, Dosimetry Parameters Estimate, and Monitoring Treatment Efficacy using Cerenkov Luminescence Imaging in Preclinical Radionuclide Therapy.}},
  url          = {{http://dx.doi.org/10.2967/jnumed.114.148544}},
  doi          = {{10.2967/jnumed.114.148544}},
  volume       = {{56}},
  year         = {{2015}},
}